After trial data for a new medicine proved inconclusive, Sarepta Therapeutics joined with the parents of sick boys to persuade officials it helped.

Topics:  sarepta therapeutics   
BING NEWS:
  • How the FDA Approved a $300,000-a-Year Drug Its Own Experts Didn't Believe Worked
    After trial data for a new medicine proved inconclusive, Sarepta Therapeutics joined with the parents of sick boys to persuade officials it helped. A man and his elder sister died of burn injuries at Udang village in Howrah district, police said today ...
    06/29/2017 - 8:32 am | View Link
  • How the FDA Approved a $300,000-a-Year Drug Its Own Experts Didn't Believe Worked
    After trial data for a new medicine proved inconclusive, Sarepta Therapeutics joined with the parents of sick boys to persuade officials it helped. Experts are calling for two toxic chemicals to be banned from use in soaps in New Zealand.Last year in the ...
    05/18/2017 - 1:00 pm | View Link
  • How the FDA Approved a $300,000-a-Year Drug Its Own Experts Didn’t Believe Worked
    Chris Garabedian, the chief executive of a pharmaceutical firm, was desperate to find a profitable drug that would reverse his company’s slow fall. They met in June 2012 at a...
    05/18/2017 - 4:24 am | View Link
  • Eteplirsen Approval Seen as Marking New Direction at FDA
    "She approved a drug not realizing that by approving the drug based on evidence that was so obviously inadequate many health insurance companies would just refuse to pay for it." Without insurance coverage, families have to pay $300,000 a year for the drug.
    12/28/2016 - 3:01 am | View Link
  • To appease a patient lobby, did the FDA approve a $300,000 drug that doesn't work?
    A couple of weeks ago, the big insurance company Anthem decided that it wouldn’t pay for Exondys 51, a drug that already had been approved by the Food and ... The drug costs $300,000 a year, and the evidence that it works is almost laughably thin.
    10/28/2016 - 9:06 am | View Link
  • More
BING SEARCH:
  • SRPT Stock Price & News
    Sarepta Therapeutics Inc. Stock - SRPT news, historical stock charts, analyst ratings, financials, and today’s Sarepta Therapeutics Inc. stock price.
    07/19/2017 - 5:07 pm | View Website
  • SRPT Stock Price
    Marathon Pharma will pause launch of Duchenne muscular dystrophy drug after outcry over $89,000 price. Feb. 13, 2017 at 4:02 p.m. ET; by Emma Court
    07/19/2017 - 1:46 pm | View Website
  • SRPT Sarepta Therapeutics, Inc. Stock Quote
    Stock screener for investors and traders, financial visualizations.
    07/19/2017 - 1:32 pm | View Website
  • GSK Stock Price
    GlaxoSmithKline PLC ADR stock price, stock quotes and financial overviews from MarketWatch.
    07/19/2017 - 7:34 am | View Website
  • 19 Facts About Abortion In America That Should Make You ...
    Every single day, a silent horror kills more Americans than were killed on 9/11. Every single year, this silent horror kills about as many Americans as have
    07/18/2017 - 8:14 pm | View Website
  • More
Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News